Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Results from InnoCare’s BTK Lymphoma Trial Published in Hematology Journal

publication date: Feb 7, 2023

Beijing InnoCare  reported the American Journal of Hematology published very positive results from a Phase II trial of its BTK inhibitor orelabrutinib. The China study enrolled 80 patients with relapsed/refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. The overall response rate was 92.5% and the complete response was 21.3%. Orelabrutinib was approved in China for three lymphoma/leukemia indications in 2020. One year ago, InnoCare out-licensed the ex-China rights for use of the drug as a MS therapy to Biogen in a deal with potential value of $937 million. More details....

Stock Symbols: (HK: 09969; SHA: 688428)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital